Differences in personality, cognitive abilities, illicit drug use, and white matter structural integrity between hallucinogen users and matched controls
Aviv Aharon-Almagor, Frederick S. Barrett
Research Square April 20, 2022 preprint DOI: 10.21203/rs.3.rs-1529935/v1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort |
|---|---|
| Sample size | 106 |
| Population | Adults from the Nathan Kline Institute-Rockland Sample database |
| Keywords | Hallucinogen Cognition Personality Clinical psychology |
| Key findings | Hallucinogen users had greater density of structural connectivity in white matter tracts supporting cognition, emotion, and creativity, and scored higher on openness and cognitive ability than non-users. |
Abstract
Abstract Recent research has demonstrated potential therapeutic effects of hallucinogens, but little is known regarding enduring effects of hallucinogens on human brain structure. Preclinical findings suggest micro-scale structural neuroplastic changes after hallucinogen administration. The current study sought to investigate the association between hallucinogen use, macroscale brain structure, personality, cognitive ability, and illicit drug use in a naturalistic sample. Data from 53 subjects reporting ever having used hallucinogens and 53 approximately hallucinogen-naïve matched controls were drawn from the Nathan Kline Institute-Rockland Sample database. Participants had completed diffusion tensor imaging, psychological, behavioral, and psychiatric assessments. Groups were compared on measures of personality, cognitive ability, history of illicit drug use, and the density of white matter tracts determined from probabilistic tractography. Hallucinogen users reported greater lifetime use of illicit drugs than controls and scored higher on measures of openness to new experiences and cognitive ability. Hallucinogen users also had greater density of structural connectivity in white matter tracts that are thought to support cognition, emotion, and creativity. These findings are consistent with reports that hallucinogen use may lead to shifts in personality as well as multiple cognitive domains. These novel findings provide clues to potential neural mechanisms underlying therapeutic effects of hallucinogens.
Citations in the library
Cites 71
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 66 more in the library